Head-to-head · WeighScore
Maves vs PauseRX
The verdict
Maves takes it — 71.8/100 to 68.5/100.
Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Maves | PauseRX |
|---|---|---|
| WeighScore | 71.8/100 | 68.5/100 |
| Grade | C | C |
| Scorecard rank | #89 | #147 |
| Semaglutide | $99/mo (starting dose, first-month rate, compounded) | $199/mo |
| Tirzepatide | Not disclosed | $249/mo (starting dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #89 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
- All 50 states covered, stated explicitly
- Both brand (Maves) and parent (Homera Health) disclosed for accountability
Where it loses points
- 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- Tirzepatide pricing not stated on the homepage — only listed as an offering
- Named medical director / clinical leadership not disclosed
- Refund and cancellation policy not detailed publicly
- Corporate address and arbitration venue not disclosed
Graded #147 · C
Strengths
- Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
- Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
- Publishes the FDA compounded-medication disclaimer
- Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
- Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation
Where it loses points
- States served not listed — site claims nationwide, but you must contact support to confirm availability
- Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
- No named medical director (Beluga Health is the network, not a named MD)
- LegitScript certification number not shown — badge only, so no direct lookup
- Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.